The lawyers representing Natco Pharma informed the court that over the past few months it had approached Novo Nordisk to communicate on its non-infringing patents but received no response, said people familiar with the matter. "A clear communication from the innovator may trigger a generic launch of the drug in India, sinking the prospects for Wegovy's sales and so that may be seen as a delaying tactic," said an expert, who did not wish to be identified.
